XML 105 R51.htm IDEA: XBRL DOCUMENT
v3.20.4

Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Data (Unaudited) |
(In millions, except per share amounts) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
2020 |  |  |  |  |  |  |  |  |
Product revenues, net | $ | 2,904.6 |  |  | $ | 2,795.7 |  |  | $ | 2,690.3 |  |  | $ | 2,301.6 |  |  | $ | 10,692.2 |
Revenues from anti-CD20 therapeutic programs | $ | 520.4 |  |  | $ | 478.3 |  |  | $ | 560.1 |  |  | $ | 419.0 |  |  | $ | 1,977.8 |
Other revenues | $ | 109.3 |  |  | $ | 407.6 |  |  | $ | 125.7 |  |  | $ | 132.0 |  |  | $ | 774.6 |
Total revenues | $ | 3,534.3 |  |  | $ | 3,681.6 |  |  | $ | 3,376.1 |  |  | $ | 2,852.6 |  |  | $ | 13,444.6 |
Gross profit (1) | $ | 3,080.0 |  |  | $ | 3,270.5 |  |  | $ | 2,927.0 |  |  | $ | 2,361.9 |  |  | $ | 11,639.4 |
Net income | $ | 1,392.6 |  |  | $ | 1,606.5 |  |  | $ | 703.9 |  |  | $ | 357.6 |  |  | $ | 4,060.5 |
Net income attributable to Biogen Inc. | $ | 1,399.1 |  |  | $ | 1,542.1 |  |  | $ | 701.5 |  |  | $ | 357.9 |  |  | $ | 4,000.6 |
Net income per share: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | $ | 8.10 |  |  | $ | 9.60 |  |  | $ | 4.47 |  |  | $ | 2.33 |  |  | $ | 24.86 |
Diluted earnings per share attributable to Biogen Inc. | $ | 8.08 |  |  | $ | 9.59 |  |  | $ | 4.46 |  |  | $ | 2.32 |  |  | $ | 24.80 |
Weighted-average shares used in calculating: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | 172.8 |  |  | 160.6 |  |  | 156.9 |  |  | 153.7 |  |  | 160.9 |
Diluted earnings per share attributable to Biogen Inc. | 173.1 |  |  | 160.9 |  |  | 157.2 |  |  | 154.0 |  |  | 161.3 |
(In millions, except per share amounts) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
2019 |  |  |  |  |  |  |  |  |
Product revenues, net | $ | 2,680.0 |  |  | $ | 2,880.3 |  |  | $ | 2,894.7 |  |  | $ | 2,924.8 |  |  | $ | 11,379.8 |
Revenues from anti-CD20 therapeutic programs | $ | 517.4 |  |  | $ | 576.4 |  |  | $ | 595.8 |  |  | $ | 600.8 |  |  | $ | 2,290.4 |
Other revenues | $ | 292.4 |  |  | $ | 160.0 |  |  | $ | 109.6 |  |  | $ | 145.7 |  |  | $ | 707.7 |
Total revenues | $ | 3,489.8 |  |  | $ | 3,616.7 |  |  | $ | 3,600.1 |  |  | $ | 3,671.3 |  |  | $ | 14,377.9 |
Gross profit (1) | $ | 2,887.8 |  |  | $ | 3,140.4 |  |  | $ | 3,170.1 |  |  | $ | 3,224.2 |  |  | $ | 12,422.5 |
Net income | $ | 1,408.8 |  |  | $ | 1,494.1 |  |  | $ | 1,545.9 |  |  | $ | 1,439.7 |  |  | $ | 5,888.5 |
Net income attributable to Biogen Inc. | $ | 1,408.8 |  |  | $ | 1,494.1 |  |  | $ | 1,545.9 |  |  | $ | 1,439.7 |  |  | $ | 5,888.5 |
Net income per share: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | $ | 7.17 |  |  | $ | 7.85 |  |  | $ | 8.40 |  |  | $ | 8.10 |  |  | $ | 31.47 |
Diluted earnings per share attributable to Biogen Inc. | $ | 7.15 |  |  | $ | 7.85 |  |  | $ | 8.39 |  |  | $ | 8.08 |  |  | $ | 31.42 |
Weighted-average shares used in calculating: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | 196.6 |  |  | 190.3 |  |  | 184.0 |  |  | 177.8 |  |  | 187.1 |
Diluted earnings per share attributable to Biogen Inc. | 197.0 |  |  | 190.4 |  |  | 184.2 |  |  | 178.2 |  |  | 187.4 |
(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration